The difference between dacomitinib and afatinib

Dacomitinib (Dacomitinib) and afatinib (Afatinib) are two commonly used targeted therapy drugs for the treatment of non-small cell lung cancer (NSCLC). They are tyrosine kinase inhibitors that block the growth and spread of tumor cells by inhibiting the epidermal growth factor receptor (EGFR) on tumor cells. These drugs may be effective if the patient's tumor has an EGFR-sensitive mutation (such as a deletion at position 19 of the EGFR gene mutation or the L858R mutation at position 21). Dacomitinib is usually taken by mouth once daily, while afatinib needs to be taken twice daily on an empty stomach. This may have implications for patient convenience and compliance.